Greenwich LifeSciences has issued an update on the status of its Form 10-K filing. The company has not provided additional details on the nature or timing of the filing in this update. Investors ...
Greenwich LifeSciences, Inc. has announced the acceptance of its abstract and associated poster for publication at the upcoming 2026 ASCO Annual Meeting. This development underscores the ...
Greenwich LifeSciences has presented preliminary data from its FLAMINGO-01 open label study at the AACR Meeting 2026. The early-stage results signal continued progress in the company's ongoing ...
Greenwich LifeSciences has released an update on its financing strategy as it adapts to evolving market realities. The company did not disclose specific details in the announcement. Investors are ...
Greenwich LifeSciences, Inc. has announced the pursuit of new patent claims stemming from the statistically significant open label immune response and recurrence rate data generated in its ...
Greenwich LifeSciences has announced it will provide an update related to its participation in the upcoming AACR Meeting. This move signals potential developments for the company, as industry ...
Greenwich LifeSciences announces an increase in the patient screening rate for its ongoing FLAMINGO-01 clinical trial. The company is advancing the enrollment phase, as reflected in the expanded ...